This Literature case, one of 26 cases in a published article, reported by a health care professional, concerns an 
adult patient whose age was between 34-80 years (exact age, gender, and ethnicity were not provided), who was 
involved in a study. 
Medical history included non-small cell lung cancer (NSCLC) stage IBS (malignant pleural effusion) or stage IV. 
Th ,.had not received .prior chemotherapy, immunotherapy, biologic therapy, or antiangiogenic drugs. 
Concomitant :  , 0  ations included cyan.. atamin  11000-mg every nine weeks starting one week before the first 
cycle of pemetrexed. Folic acid 1 mg was also administered orally every day beginning one week before the first 
cycle of pemetrexed. 
The patient received pemetrexed (unknown manufacturer) 500 mg/m2 as a 10 minute intravenous (IV) infusion on 
day one immediately fol o  o by ca ,000Iatin as a 30 minute IV infusion on day one, and then bevacizumab 15 
mg/kg as a 30-90 minute IV infusion, on day one for treatment of advanced nonsquamous NSCLC sometime 
Print Time: 12-SEP-2014 01:09 PM If a field is blank, there is no data for that field Page 125  of 324 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
twetween Sep2005-Dec2009. On an unspecified date during cycles 1-6, the patient experienced Grade 3 dyspnea. 
Treatment measures, event outcome, and pemetrexed status were not provided. 
The author related the event to pemetrexed therapy. 
This case is associated with US201211002516 
Literature Citation: Stevenson James P, Langer Corey J, Somer Robert A, Evans Tracey L, Rajagopalan Kumar, 
Krieger Kimberly. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and 
cad tin in advanced, nonsquamous nonsrnall cell lung cancer. Cancer. 2012; 118 5580-5587.